SPAC Drugs Made In America Acquisition files for a $500 million IPO
I'm PortAI, I can summarize articles.
SPAC Drugs Made In America Acquisition plans to raise $500 million in an IPO to target a pharmaceutical business in the US. The company, led by CEO Lynn Stockwell and CFO Glenn Worman, was founded in 2024 and will list on Nasdaq under the symbol DMAAU. EF Hutton is the sole bookrunner.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments